Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01861002 · ClinicalTrials.gov registry record · Phase 1

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

A Phase 1 study of Lymphoblastic Leukemia, Acute, Childhood and Myelogenous Leukemia, Acute, Childhood, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target
20
Study locations

NCT01861002 is a Phase 1 study of Lymphoblastic Leukemia, Acute, Childhood and Myelogenous Leukemia, Acute, Childhood that has completed, run by Therapeutic Advances in Childhood Leukemia Consortium. The registered enrollment target is 15 participants, below the 42-participant average among 4 other Lymphoblastic Leukemia, Acute, Childhood trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01861002, a Phase 1 study of Lymphoblastic Leukemia, Acute, Childhood and Myelogenous Leukemia, Acute, Childhood, has completed, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase I study with a conditional cohort expansion phase to evaluate the feasibility of, and to obtain preliminary efficacy data about, pretreatment with Azacytidine (AZA) for 5 days followed by fludarabine/cytarabine chemotherapy regimen in pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients who are refractory to primary treatment or who relapsed.

Interventions

  • DRUG Fludarabine
  • DRUG Cytarabine
  • DRUG Azacytidine
  • DRUG Intrathecal (IT) Cytarabine
  • DRUG Intrathecal Methotrexate (IT MTX)

Study Locations (20)

California

  • Childrens Hospital Los Angeles - Los Angeles
  • UCSF School of Medicine - San Francisco

Ohio

  • Rainbow Babies & Children's Hospital - Cleveland
  • Nationwide Childrens Hospital - Columbus

Texas

  • University of Texas at Southwestern - Dallas
  • Cook Children's Medical Center - Fort Worth

District of Columbia

  • Children's National Medical Center - Washington D.C.

Georgia

  • Children's Healthcare of Atlanta, Emory University - Atlanta

Maryland

  • Johns Hopkins University - Baltimore

Massachusetts

  • Dana Farber - Boston

Michigan

  • C.S. Mott Children's Hospital - Ann Arbor

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2013-05-22
Est. Completion 2014-07-28
Phase Phase 1

What the Registry Record Tells You About NCT01861002

The ClinicalTrials.gov registry entry for NCT01861002 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 42-participant average among 4 other Lymphoblastic Leukemia, Acute, Childhood trials with a reported enrollment target (64% lower). The listed sponsor is Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lymphoblastic Leukemia, Acute, Childhood appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.

NCT01861002 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Ohio, Texas.

Frequently Asked Questions

What is clinical trial NCT01861002 about?

NCT01861002 is a clinical study titled "A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML". This is a Phase I study with a conditional cohort expansion phase to evaluate the feasibility of, and to obtain preliminary efficacy data about, pretreatment with Azacytidine (AZA) for 5 days followed by fludarabine/cytarabine chemotherapy regimen in pediatric acute myeloid leukemia (AML) and acute ...

What is the current status of trial NCT01861002?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2013-05-22. Estimated completion is 2014-07-28.

What conditions does trial NCT01861002 study?

This clinical trial studies the following conditions: Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood.

What interventions are being tested in trial NCT01861002?

The interventions under investigation include: Fludarabine (DRUG), Cytarabine (DRUG), Azacytidine (DRUG), Intrathecal (IT) Cytarabine (DRUG), Intrathecal Methotrexate (IT MTX) (DRUG).

Who is sponsoring clinical trial NCT01861002?

This trial is sponsored by Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01861002 being conducted?

This trial has 20 study locations across California, District of Columbia, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphoblastic Leukemia, Acute, Childhood

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.